ArticleFrontiers in medicine2025
HTLV-1 and HTLV-2 infections significantly alter small RNA expression in asymptomatic carriers.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Case of concurrent ALS and human T-cell leukaemia virus type 1-associated myositis.BMJ case reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study investigates the impact of HTLV-2 infection on small RNA (sRNA) expression profiles, building on previous findings related to HTLV-1. Methods: Using Illumina Massive Parallel Sequencing, we analyzed sRNA profiles from asymptomatic HTLV-1 and HTLV-2 infected individuals and healthy controls. Results: Our results reveal significant differential expression of 331 known and 441 novel sRNAs among the groups, including miRNAs, piRNAs, and tRNAs. Notably, distinct clusters of sRNA expression patterns were identified, with specific miRNAs showing significant upregulation or downregulation in HTLV-1 and HTLV-2 infections. Gene Ontology analysis indicated significant involvement of target genes in transcription regulation and RNA-binding processes, while KEGG pathway analysis highlighted enrichment in cancer-related pathways and signaling cascades such as FoxO, Ras, and MAPK. Network analysis identified key miRNAs, such as hsa-miR-20b-5p and hsa-let-7e-5p, as central regulators with extensive interactions, suggesting their potential role in the pathogenesis and immune response of HTLV infections. Discussion: These findings provide a foundation for future research into the molecular mechanisms of HTLV infections and the development of targeted therapies. The identified sRNAs, especially important miRNAs such as hsa-miR-20b-5p and hsa-let-7e-5p, could serve as potential biomarkers for disease progression or as therapeutic targets to modulate the immune response and disrupt viral pathogenesis. This opens up new avenues for precision medicine in HTLV-associated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.